However, the same trial showed harm for ischemic stroke patients and, thus, should not be pursued without confirming the diagnosis of ICH [21], highlighting the need for approaches to rapidly distinguish ICH from ischemic stroke patients in the pre-hospital setting, potentially with the help of mobile stroke units or biomarker-based detection of ICH [22], such as using point-of-care glial fibrillary acid protein [23], in the field. The gene discussed is GFAP; the disease is ischemic stroke.